Iovance Biotherapeutics, Inc.
IOVA
$3.78
-$0.10-2.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 313.44M | 296.98M | 300.80M | 301.18M | 359.71M |
| Total Receivables | 81.76M | 82.45M | 66.76M | 59.94M | 70.94M |
| Inventory | 58.38M | 51.68M | 51.71M | 49.83M | 65.55M |
| Prepaid Expenses | 12.93M | 11.58M | 9.82M | 11.55M | 15.89M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | 559.00K |
| Total Current Assets | 466.50M | 442.69M | 429.09M | 422.50M | 512.65M |
|
|
|||||
| Total Current Assets | 466.50M | 442.69M | 429.09M | 422.50M | 512.65M |
| Net Property, Plant & Equipment | 175.78M | 177.01M | 175.41M | 172.42M | 162.49M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | 269.10M | 279.32M | 285.21M | 296.25M | 285.36M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 14.28M | 14.15M | 15.24M | 16.26M | 6.25M |
| Total Assets | 925.67M | 913.17M | 904.95M | 907.44M | 966.74M |
|
|
|||||
| Total Accounts Payable | 37.45M | 22.16M | 31.24M | 32.00M | 28.49M |
| Total Accrued Expenses | 83.50M | 104.71M | 82.91M | 78.05M | 77.49M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 3.90M | 5.04M | 7.28M | 8.07M | 9.50M |
| Total Finance Division Other Current Liabilities | 4.57M | 6.45M | 4.36M | 11.03M | 7.22M |
| Total Other Current Liabilities | 4.57M | 6.45M | 4.36M | 11.03M | 7.22M |
| Total Current Liabilities | 129.42M | 138.36M | 125.79M | 129.16M | 122.69M |
|
|
|||||
| Total Current Liabilities | 129.42M | 138.36M | 125.79M | 129.16M | 122.69M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 43.88M | 44.40M | 45.21M | 45.10M | 44.22M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 30.61M | 31.83M | 31.67M | 34.70M | 31.96M |
| Total Liabilities | 203.91M | 214.59M | 202.66M | 208.95M | 198.88M |
|
|
|||||
| Common Stock & APIC | 3.56B | 3.46B | 3.39B | 3.29B | 3.26B |
| Retained Earnings | -2.85B | -2.78B | -2.70B | -2.61B | -2.50B |
| Treasury Stock & Other | 12.65M | 16.44M | 16.10M | 20.86M | 6.29M |
| Total Common Equity | 721.75M | 698.58M | 702.29M | 698.49M | 767.86M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | 2.00K | 2.00K | 2.00K | 2.00K | 2.00K |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | 2.00K | 2.00K | 2.00K | 2.00K | 2.00K |
|
|
|||||
| Total Common Equity | 721.75M | 698.58M | 702.29M | 698.49M | 767.86M |
| Total Preferred Equity | 2.00K | 2.00K | 2.00K | 2.00K | 2.00K |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 721.75M | 698.58M | 702.29M | 698.49M | 767.87M |
|
|
|||||